MOZE BARRY 4

Accession 0001209191-21-063200

CIK 0001492426other

View on SEC.gov Company Profile

Filed

Nov 4, 8:00 PM ET

Accepted

Nov 5, 5:00 PM ET

Size

27.3 KB

Accession

0001209191-21-063200

Insider Transaction Report

Form 4

Period: 2021-11-04

Horizon Therapeutics Public Ltd CoHZNP

MOZE BARRY

EVP, Corporate Dev't.

Transactions

Sale
Ordinary Shares
2021-11-04$112.60/sh−6,151$692,603→ 106,035 total
Sale
Ordinary Shares
2021-11-04$114.43/sh−6,763$773,890→ 81,405 total
Exercise/Conversion
Ordinary Shares
2021-11-04$22.14/sh+3,000$66,420→ 78,681 total
Exercise/Conversion
Ordinary Shares
2021-11-04$11.81/sh+443$5,232→ 79,124 total
Exercise/Conversion
Ordinary Shares
2021-11-04$14.48/sh+72,300$1,046,904→ 151,424 total
Sale
Ordinary Shares
2021-11-04$111.75/sh−15,856$1,771,908→ 112,186 total
Sale
Ordinary Shares
2021-11-04$113.56/sh−17,867$2,028,977→ 88,168 total
Exercise/Conversion
Stock Option (Right to Buy)
2021-11-04−3,000→ 162,181 total
Exercise: $22.14Exp: 2025-03-22→ Ordinary Shares (3,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2021-11-04−72,300→ 0 total
Exercise: $14.48Exp: 2024-06-05→ Ordinary Shares (72,300 underlying)
Sale
Ordinary Shares
2021-11-04$110.17/sh−23,382$2,575,995→ 128,042 total
Sale
Ordinary Shares
2021-11-04$115.45/sh−5,724$660,836→ 75,681 total
Exercise/Conversion
Stock Option (Right to Buy)
2021-11-04−443→ 0 total
Exercise: $11.81Exp: 2024-09-11→ Ordinary Shares (443 underlying)

Footnotes (8)

[F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021.
[F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.985 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.10 to $112.07 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F4]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.12 to $113.085 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F5]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.14 to $114.135 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F6]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.14 to $115.12 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F7]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.15 to $115.88 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F8]The stock option is fully vested and exercisable.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

Horizon Therapeutics Public Ltd Co

CIK 0001492426

→

Entity typeother

Related Parties

filerCIK 0001619500

Filing Metadata

Form type: 4
Filed: Nov 4, 8:00 PM ET
Accepted: Nov 5, 5:00 PM ET
Size: 27.3 KB

View on SEC.gov